Cell­tri­on's rheuma­toid arthri­tis drug meets both end­points in PhI­II; New com­pa­ny Tri­bune emerges to take on fi­brot­ic dis­eases

Cell­tri­on Health­care an­nounced pos­i­tive re­sults from its year-long Phase III tri­al of its rheuma­toid arthri­tis drug Yu­fly­ma in pa­tients re­ceiv­ing ther­a­py on Tues­day, as the tri­al met both the pri­ma­ry and sec­ondary end­points.

The tri­al in pa­tients with mod­er­ate-to-se­vere RA test­ed 3 groups: 1 in pa­tients who re­ceived 40 mg of CT-P17 or 1 that re­ceived the ref­er­ence drug Hu­mi­ra, and a third that switched from Hu­mi­ra to CP-P17 halfway through the tri­al, for the re­main­der of the year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.